We provide you with 20 years of free, institutional-grade data for IMGN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IMGN. Explore the full financial landscape of IMGN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Enyedy Mark J | Sale | -20,107 | $29.28 | $588,733 | 2024-02-06 |
| Enyedy Mark J | Derivatives Exercise | 51,234 | 2024-02-06 | ||
| Enyedy Mark J | RSU | 51,234 | 2024-02-06 | ||
| Lentini Renee | Sale | -2,631 | $29.3 | $77,088 | 2024-02-06 |
| Lentini Renee | Derivatives Exercise | 8,435 | 2024-02-06 | ||
| Lentini Renee | RSU | 8,435 | 2024-02-06 | ||
| Coen Stacy Ann | Sale | -4,583 | $29.3 | $134,282 | 2024-02-06 |
| Coen Stacy Ann | Derivatives Exercise | 14,350 | 2024-02-06 | ||
| Coen Stacy Ann | RSU | 14,350 | 2024-02-06 | ||
| Wingrove Theresa | Sale | -12,027 | $29.3 | $352,391 | 2024-02-06 |
| Wingrove Theresa | Derivatives Exercise | 29,640 | 2024-02-06 | ||
| Wingrove Theresa | RSU | 29,640 | 2024-02-06 | ||
| Wingrove Theresa | Sale | -187,667 | $29.64 | $5,562,450 | 2024-01-18 |
| Wingrove Theresa | Derivatives Exercise | 187,667 | 2024-01-18 | ||
| Goldberg Mark Alan | Grant, award...etc | 569 | $29.65 | 2024-01-03 | |
| Arbuckle Stuart A | Grant, award...etc | 442 | $29.65 | 2024-01-03 | |
| Thackray Helen M. | Grant, award...etc | 252 | $29.65 | 2024-01-03 | |
| Coen Stacy Ann | Grant, award...etc | 367 | $16.01 | 2024-01-03 | |
| Coen Stacy Ann | Derivatives Exercise | 30,000 | 2024-01-03 | ||
| VASCONCELLES MICHAEL | Grant, award...etc | 1,327 | $16.01 | 2024-01-03 | |
| Wingrove Theresa | Grant, award...etc | 615 | $16.01 | 2024-01-03 | |
| Lentini Renee | Grant, award...etc | 467 | $16.01 | 2024-01-03 | |
| Lentini Renee | Sale | -6,548 | $29.74 | $194,738 | 2023-12-27 |
| Lentini Renee | Derivatives Exercise | 15,000 | 2023-12-27 | ||
| Lentini Renee | RSU | 15,000 | 2023-12-27 | ||
| Wingrove Theresa | Sale | -117,445 | $29.4 | $3,452,883 | 2023-12-19 |
| Wingrove Theresa | Derivatives Exercise | 117,445 | 2023-12-19 | ||
| MITCHELL DEAN J | Derivatives Exercise | 10,000 | 2023-12-19 | ||
| Coen Stacy Ann | Sale | -3,826 | $29.2 | $111,719 | 2023-12-05 |
| Peterson Kristine | Sale | -20,000 | $28.9 | $578,000 | 2023-12-05 |
| Peterson Kristine | Derivatives Exercise | 20,000 | 2023-12-05 | ||
| Wingrove Theresa | Sale | -171,216 | $16.66 | $2,852,459 | 2023-12-01 |
| Wingrove Theresa | Derivatives Exercise | 171,216 | 2023-12-01 | ||
| Wingrove Theresa | Sale | -166,725 | $15.85 | $2,642,591 | 2023-11-17 |
| Wingrove Theresa | Derivatives Exercise | 166,725 | 2023-11-17 | ||
| Coen Stacy Ann | Sale | -108,609 | $16.01 | $1,738,830 | 2023-11-17 |
| Coen Stacy Ann | Derivatives Exercise | 108,609 | 2023-11-17 | ||
| Lentini Renee | Sale | -219,545 | $15.29 | $3,356,843 | 2023-11-08 |
| Lentini Renee | Derivatives Exercise | 120,528 | 2023-11-08 | ||
| Wingrove Theresa | Sale | -19,517 | $16.66 | $325,153 | 2023-11-08 |
| Wingrove Theresa | Derivatives Exercise | 19,517 | 2023-11-08 | ||
| Wallace Richard John | Derivatives Exercise | 10,000 | 2023-11-08 | ||
| Goldberg Mark Alan | Derivatives Exercise | 0 | 2023-11-01 | ||
| Wingrove Theresa | Sale | -192,004 | $14.4 | $2,764,858 | 2023-10-18 |
| Wingrove Theresa | Derivatives Exercise | 192,004 | 2023-10-18 | ||
| Thackray Helen M. | Grant, award...etc | 472 | $15.87 | 2023-10-02 | |
| Arbuckle Stuart A | Grant, award...etc | 827 | $15.87 | 2023-10-02 | |
| Goldberg Mark Alan | Grant, award...etc | 1,063 | $15.87 | 2023-10-02 | |
| MITCHELL DEAN J | Derivatives Exercise | 10,000 | 2023-09-26 | ||
| Wingrove Theresa | Sale | -192,013 | $15.44 | $2,964,681 | 2023-09-19 |
| Wingrove Theresa | Derivatives Exercise | 108,668 | 2023-09-19 | ||
| Peterson Kristine | Derivatives Exercise | 0 | 2023-09-14 | ||
| MCCLUSKI STEPHEN C | Derivatives Exercise | 0 | 2023-09-14 | ||
| Lentini Renee | Derivatives Exercise | 25,141 | 2023-09-14 | ||
| Coen Stacy Ann | Derivatives Exercise | 26,006 | 2023-09-11 | ||
| Coen Stacy Ann | Sale | -100,210 | $14.2 | $1,422,982 | 2023-08-11 |
| Coen Stacy Ann | Derivatives Exercise | 100,210 | 2023-08-11 | ||
| Enyedy Mark J | Sale | -3,007,554 | $17.45 | $52,481,817 | 2023-08-04 |
| Enyedy Mark J | Derivatives Exercise | 3,119,375 | 2023-08-04 | ||
| Lentini Renee | Sale | -148,277 | $17.55 | $2,602,261 | 2023-08-04 |
| Lentini Renee | Derivatives Exercise | 199,310 | 2023-08-04 | ||
| Coen Stacy Ann | Sale | -84,581 | $18.12 | $1,532,608 | 2023-08-04 |
| Coen Stacy Ann | Derivatives Exercise | 84,581 | 2023-08-04 | ||
| Thackray Helen M. | Grant, award...etc | 397 | $18.87 | 2023-07-05 | |
| Goldberg Mark Alan | Grant, award...etc | 894 | $18.87 | 2023-07-05 | |
| Enyedy Mark J | Grant, award...etc | 5,241 | $4.05 | 2023-07-05 | |
| Wingrove Theresa | Grant, award...etc | 2,811 | $4.05 | 2023-07-05 | |
| Coen Stacy Ann | Grant, award...etc | 3,792 | $4.05 | 2023-07-05 | |
| Berkenblit Anna | Grant, award...etc | 3,264 | $4.05 | 2023-07-05 | |
| Lentini Renee | Grant, award...etc | 3,195 | $4.05 | 2023-07-05 | |
| Arbuckle Stuart A | Grant, award...etc | 695 | $18.87 | 2023-07-05 | |
| Thackray Helen M. | Grant, award...etc | 1,953 | $3.84 | 2023-04-04 | |
| Goldberg Mark Alan | Grant, award...etc | 4,394 | $3.84 | 2023-04-04 | |
| Arbuckle Stuart A | Grant, award...etc | 3,417 | $3.84 | 2023-04-04 |
The information provided in this report about IMGN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
ImmunoGen, Inc(NASDAQ:IMGN) 
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ov...
Website: http://www.immunogen.com
Founded: 1981
Full Time Employees: 75
Sector: Healthcare
Industry: Biotechnology
